EYENOVIA INC. - COMMON STOCK

Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue

15 6月 2021 08:00:02 条件 Nasdaq GlobeNewswire

Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia

25 5月 2021 09:03:54 条件 Nasdaq GlobeNewswire

Eyenovia Reports First Quarter 2021 Financial Results

12 5月 2021 16:05:01 条件 Nasdaq GlobeNewswire

Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank

10 5月 2021 08:30:00 条件 Nasdaq GlobeNewswire

Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12

05 5月 2021 08:00:01 条件 Nasdaq GlobeNewswire

Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results

25 3月 2021 16:05:00 条件 Nasdaq GlobeNewswire

Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25

18 3月 2021 08:00:00 条件 Nasdaq GlobeNewswire

Eyenovia to Participate in the 33rd Annual Roth Conference

10 3月 2021 08:00:01 条件 Nasdaq GlobeNewswire

Eyenovia to Host Key Opinion Leader Webinar on Presbyopia

16 2月 2021 08:00:01 条件 Nasdaq GlobeNewswire

Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event

06 1月 2021 08:00:01 条件 Nasdaq GlobeNewswire